The FDA has accepted the sNDA for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung disease.

Related Keywords

Colorado , United States , Robin Deterding , Drug Administration , New Drug Application , Breathing Institute , Hospital Colorado ,